GSK paid $50 million upfront to license Noetik’s foundation AI models for colorectal and non‑small‑cell lung cancer, moving from bespoke AI services to a subscription licensing framework. The agreement gives GSK non‑exclusive access to models that simulate tumor gene expression, cell states and tumor‑immune interactions for target selection and efficacy prediction. Noetik will generate bespoke spatial biology datasets for GSK and retain a subscription model for access and annual fees. Both parties positioned the deal as a new paradigm—licensing pretrained biological models rather than single‑asset collaborations—and GSK said it will integrate the models into discovery and early development pipelines. The pact underscores continued pharma investment in foundation‑model AI for biologic and target selection, and validates Noetik’s spatial‑data training approach as an industry asset class.